Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Interest Expenses (2022 - 2025)

TScan Therapeutics (TCRX) has disclosed Interest Expenses for 4 consecutive years, with $702000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Interest Expenses fell 10.46% to $702000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.8 million, a 24.2% decrease, with the full-year FY2025 number at $2.8 million, down 24.2% from a year prior.
  • Interest Expenses was $702000.0 for Q4 2025 at TScan Therapeutics, roughly flat from $699000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $982000.0 in Q3 2023 to a low of $679000.0 in Q1 2025.
  • A 4-year average of $858153.8 and a median of $952000.0 in 2024 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: increased 0.31% in 2024, then dropped 29.2% in 2025.
  • TScan Therapeutics' Interest Expenses stood at $975000.0 in 2022, then decreased by 12.62% to $852000.0 in 2023, then decreased by 7.98% to $784000.0 in 2024, then dropped by 10.46% to $702000.0 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Interest Expenses are $702000.0 (Q4 2025), $699000.0 (Q3 2025), and $689000.0 (Q2 2025).